A Phase 3 interventional study of Baloxavir Marboxil and Placebo in Influenza, sponsored by Hoffmann-La Roche. Completed at 170 sites in 28 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-01-06.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing baloxavir in Influenza, Human — 7 open to participants now, 7 under way, 5 of them phase 3. baloxavir · Influenza, Human.
Among the 18 studies testing baloxavir in Influenza, Human, this one is the 12th largest by enrollment, is one of 4 that started in 2019, is one of 12 in phase 3, and was the 6th registered.
2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.
Browse Influenza, Human studies →7 of the 18 studies testing baloxavir in Influenza, Human are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in China
Ages 5+ · Healthy volunteers
Unity Health Toronto · Sites in Canada
Ages 18+
Dre Pauline Vetter · Sites in Switzerland
Ages 18+
Hoffmann-La Roche · Sites in United States, Bulgaria, Poland and 1 more country
Ages 3 wk–11 yrs
University of Oxford · Sites in Brazil, Laos, Nepal and 1 more country
Ages 18–60
By country, each count listing its studies:
baloxavir: first FDA approval 2018 (XOFLUZA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 13 · Phase 4 3
First in 2016; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 363 is above the median of 227 across 1,957 interventional studies indexed under Influenza, Human.
Median enrollment 483 across the 18 interventional studies. Of the 10 that completed or were terminated, 8 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 18 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
22 studies in Influenza, Human by Hoffmann-La Roche: 2 open now, 2 under way, 2 of them phase 3. Of 20 finished, 16 (80%) have results posted.
Among the 22 studies in Influenza, Human by Hoffmann-La Roche, this one is the 4th largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2019, is one of 10 in phase 3, and was the 18th registered.
Hoffmann-La Roche’s Influenza, Human studies by the year they started, since 2006.
5 of the studies testing baloxavir in Influenza, Human that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07314905Phase 3Unity Health TorontoAdaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp) | 2027-03-31 |
| NCT06653569Phase 3Dre Pauline VetterEfficacy of Baloxavir Against Influenza in Hospitalized Patients: The INFLUENT Study (INpatients inFLUENza Treatment) | 2027-04 |
| NCT07827599Phase 3Hoffmann-La RocheA Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants | 2027-04-30 |
| NCT06094010Phase 3Hoffmann-La RocheA Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts | 2027-05-11 |
| NCT05648448University of OxfordA Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza | 2027-01-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 18 studies testing baloxavir in Influenza, Human, from their registry updates:
Among Hoffmann-La Roche’s 22 in Influenza, Human:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy, safety, and pharmacokinetics of baloxavir marboxil in combination with a standard-of-care (SOC) neuraminidase inhibitor (NAI) (i.e., oseltamivir, zanamivir, or peramivir) compared with a matching placebo in combination with a SOC NAI in hospitalized patients with influenza.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive at least two doses of baloxavir marboxil on Days 1 and 4. A third dose of Baloxavir will be given on Day 7 for participants who have not improved according to protocol defined criteria on Day 5. Study treatment will be given in combination with SOC NAI (i.e., oseltamivir, zanamivir, or peramivir) in accordance with local clinical practice.
Drug: Baloxavir Marboxil
Participants will receive at least two doses of placebo on Day 1 and 4. A third dose of placebo will be given on Day 7 for participants who have not improved according to protocol defined criteria on Day 5. Study treatment will be given in combination with SOC NAI (i.e., oseltamivir, zanamivir, or peramivir) in accordance with local clinical practice.
Other: Placebo
Baloxavir marboxil will be administered as a weight-based dose on Days 1 and 4. A third dose will be given on Day 7 for participants who have not improved according to protocol defined criteria on Day 5.
Participants will receive matching placebo on Days 1, 4 and 7.
Time to Clinical Improvement
Time to Clinical Improvement (TTCI) is defined as Time to Hospital Discharge OR Time to NEWS2 (National Early Warning Score 2) of ≤ 2 maintained for 24 hours.
Time frame: Up to Day 35
Response Rates of the 6-Point Ordinal Scale at Day 7
The ordinal scale categories are: Category 1) Discharged (or "ready for discharge") Category 2) Non-ICU hospital ward (or "ready for hospital ward") not requiring supplemental oxygen/non-invasive ventilation Category 3) Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen/non-invasive ventilation Category 4) ICU without mechanical (invasive) ventilation (or "ready for ICU admission") Category 5) Mechanical (invasive) ventilation Category 6) Death
Time frame: Day 7
Time to Clinical Response
Time to Clinical Response is based on temperature ranges, oxygen saturation, respiratory status, heart rate, and hospitalization status.
Time frame: Up to Day 35
Percentage of Participants on Mechanical Ventilation
Time frame: Up to Day 35
Duration of Mechanical Ventilation
Time frame: Up to Day 35
Percentage of Participants Requiring ICU Stay
Time frame: Up to Day 35
Duration of ICU Stay
Time frame: Up to Day 35
Time to Clinical Failure
Time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission, corresponding to ordinal scale categories 6, 5, and 4, respectively, from baseline
Time frame: Up to Day 35
Time to Hospital Discharge
Time frame: Up to Day 35
Percentage of Participants With Post-Treatment Influenza-Related Complications
Influenza-related complications included pneumonia, myositis or rhabdomyolysis, encephalitis or encephalopathy, myocarditis and/or pericarditis, otitis media, sinusitis, exacerbation of COPD/asthma, sepsis, acute lung injury or acute respiratory distress syndrome.
Time frame: Up to Day 35
Mortality Rate at Day 7
Time frame: Up to Day 7
Mortality Rate at Day 28
Time frame: Up to Day 28
Time to NEWS2 of ≤ 2 Maintained for 24 Hours
A score of 0 (Range 0 - 3) indicates normal health conditions.
Time frame: Up to Day 35
Time to Cessation of Viral Shedding by Virus Titer
Time to cessation of viral shedding by virus titer is defined as the time, in hours, between the initiation of study treatment and first time when the influenza virus titer is below the limit of detection (0.75 log10 TCID50/mL)
Time frame: Screening (baseline) and on Days 2, 3, 4, 5, 7, and 10
Change From Baseline in Influenza Virus Titer at Each Timepoint
Influenza virus titer is the quantity of influenza virus in a given volume within the samples obtained from nasal swabs. If influenza virus titer was less than the lower limit of quantification, the virus titer was imputed as 0.749 (log10TCID50/mL). A lower value indicates lower viral titer.
Time frame: Days 2, 3, 4, 5, 7, and 10
Percentage of Participants With Positive Influenza Virus Titer at Each Timepoint
Influenza virus titer is the quantity of influenza virus in a given volume within the samples obtained from nasal swabs. If influenza virus titer was less than the lower limit of quantification, the virus titer was imputed as 0.749 (log10 TCID50/mL). A lower value indicates lower viral titer.
Time frame: Days 2, 3, 4, 5, 7, and 10
Area Under the Curve in Virus Titer
Time frame: Days 1, 2, 3, 4, 5, 7, and 10
Time to Cessation of Viral Shedding by RT-PCR
Time to cessation of viral shedding by RT-PCR, in hours, is defined as the time between the initiation of study treatment and first time when the virus RNA by RT-PCR is below the limit of detection (2.05 for flu A and 2.83 for flu B log10 virus particles/mL)
Time frame: Screening (baseline) and on Days 2, 3, 4, 5, 7, and 10
Change From Baseline in the Amount of Virus RNA (RT-PCR) at Each Timepoint
If the amount of virus RNA was less than the lower limit of quantification, the amount of virus RNA was imputed as 2.18 for flu A and 2.93 for flu B (log10 virus particles/mL)
Time frame: Days 2, 3, 4, 5, 7, and 10
Percentage of Participants Positive by RT-PCR at Each Timepoint
If the amount of virus RNA was less than the lower limit of quantification, the amount of virus RNA was imputed as 2.18 for flu A and 2.93 for flu B (log10 virus particles/mL)
Time frame: Days 2, 3, 4, 5, 7, and 10
Area Under the Curve in the Amount of Virus RNA (RT-PCR)
Time frame: Days 1, 2, 3, 4, 5, 7, and 10
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. A serious adverse event (SAE) is any significant hazard, contraindication, side effect that is fatal or life-threatening, requires hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability/ incapacity, is a congenital anomaly/ birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above.
Time frame: Up to Day 35
Percentage of Participants With AEs and SAEs Leading to Discontinuation From Treatment
Discontinuation from study treatment.
Time frame: Up to Day 35
Percentage of Participants With Any Post-Treatment ALT and AST Above Baseline and >3 × ULN, >5 × ULN, >10 × ULN
ALT = alanine aminotransferase AST = aspartate transaminase
Time frame: Up to Day 35
Plasma Concentration of Baloxavir (Active Metabolite) at Specified Time Points
Time frame: Day 1, 2, 4, 5, 7 and 8
Area Under the Concentration to Time Curve From Time 0 to 72 Hours (AUC0-72) of Baloxavir
Time frame: 0, 0.5, 2, 4, 10, 24, 72 hours from dose on Day 1 and on Day 4, and Day 7, Day 8
Maximum Plasma Concentration (Cmax) of Baloxavir
Time frame: 0, 0.5, 2, 4, 10, 24, 72 hours from dose on Day 1 and on Day 4, and Day 7, Day 8
Apparent Half-Life (T1/2) of Baloxavir
Time frame: 0, 0.5, 2, 4, 10, 24, 72 hours from dose on Day 1 and on Day 4, and Day 7, Day 8
Concentration at 24 Hours (C24) of Baloxavir
Time frame: 0, 0.5, 2, 4, 10, 24, 72 hours from dose on Day 1 and on Day 4, and Day 7, Day 8
A total of 363 patients received at least one dose of study treatment and were included in the analyses of safety and efficacy.
| Milestone | Baloxavir Marboxil | Placebo |
|---|---|---|
| Started | 239 | 124 |
| Completed | 217 | 104 |
| Not completed | 22 | 20 |
| Withdrew: Adverse event | 3 | 0 |
| Withdrew: Death | 4 | 7 |
| Withdrew: Lost to follow-up | 3 | 2 |
| Withdrew: Patient not available | 0 | 2 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 11 | 9 |
Time to Clinical Improvement (TTCI) is defined as Time to Hospital Discharge OR Time to NEWS2 (National Early Warning Score 2) of ≤ 2 maintained for 24 hours.
| hours | Baloxavir Marboxil | Placebo |
|---|---|---|
| Time to Clinical Improvement | 97.5 (75.9 to 117.2) | 100.2 (75.9 to 144.4) |
The ordinal scale categories are: Category 1) Discharged (or "ready for discharge") Category 2) Non-ICU hospital ward (or "ready for hospital ward") not requiring supplemental oxygen/non-invasive ventilation Category 3) Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen/non-invasive ventilation Category 4) ICU without mechanical (invasive) ventilation (or "ready for ICU admission") Category 5) Mechanical (invasive) ventilation Category 6) Death
| percentage of participants | Baloxavir Marboxil | Placebo |
|---|---|---|
| Category 1 | 49.2 | 45.4 |
| Category 2 | 22.6 | 24.1 |
| Category 3 | 20.1 | 22.2 |
| Category 4 | 4.0 | 1.9 |
| Category 5 | 3.5 | 4.6 |
| Category 6 | 0.5 | 1.9 |
Time to Clinical Response is based on temperature ranges, oxygen saturation, respiratory status, heart rate, and hospitalization status.
| hours | Baloxavir Marboxil | Placebo |
|---|---|---|
| Time to Clinical Response | 138.3 (120.0 to 161.1) | 145.1 (128.0 to 187.2) |
| percentage of participants | Baloxavir Marboxil | Placebo |
|---|---|---|
| Percentage of Participants on Mechanical Ventilation | 5.3 | 6.1 |
| hours | Baloxavir Marboxil | Placebo |
|---|---|---|
| Duration of Mechanical Ventilation | 150.25 (18.0 to 465.0) | 91.00 (24.0 to 407.0) |
| percentage of participants | Baloxavir Marboxil | Placebo |
|---|---|---|
| Percentage of Participants Requiring ICU Stay | 4.3 | 3.5 |
| hours | Baloxavir Marboxil | Placebo |
|---|---|---|
| Duration of ICU Stay | 138.55 (23.7 to 362.0) | 71.78 (18.7 to 139.4) |
Time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission, corresponding to ordinal scale categories 6, 5, and 4, respectively, from baseline
| hours | Baloxavir Marboxil | Placebo |
|---|---|---|
| Time to Clinical Failure | NA (NA to NA) | NA (NA to NA) |
| hours | Baloxavir Marboxil | Placebo |
|---|---|---|
| Time to Hospital Discharge | 166.7 (144.7 to 190.7) | 167.3 (146.4 to 211.1) |
Influenza-related complications included pneumonia, myositis or rhabdomyolysis, encephalitis or encephalopathy, myocarditis and/or pericarditis, otitis media, sinusitis, exacerbation of COPD/asthma, sepsis, acute lung injury or acute respiratory distress syndrome.
| percentage of participants | Baloxavir Marboxil | Placebo |
|---|---|---|
| Percentage of Participants With Post-Treatment Influenza-Related Complications | 10.6 | 14.0 |
| percentage of participants | Baloxavir Marboxil | Placebo |
|---|---|---|
| Mortality Rate at Day 7 | 0.5 (0.01 to 2.65) | 2.6 (0.55 to 7.50) |
| percentage of participants | Baloxavir Marboxil | Placebo |
|---|---|---|
| Mortality Rate at Day 28 | 1.9 (0.53 to 4.85) | 5.3 (1.96 to 11.10) |
A score of 0 (Range 0 - 3) indicates normal health conditions.
| hours | Baloxavir Marboxil | Placebo |
|---|---|---|
| Time to NEWS2 of ≤ 2 Maintained for 24 Hours | 106.3 (88.3 to 138.3) | 127.2 (77.4 to 156.3) |
Time to cessation of viral shedding by virus titer is defined as the time, in hours, between the initiation of study treatment and first time when the influenza virus titer is below the limit of detection (0.75 log10 TCID50/mL)
| hours | Baloxavir Marboxil | Placebo |
|---|---|---|
| Time to Cessation of Viral Shedding by Virus Titer | 23.9 (23.2 to 24.5) | 63.7 (46.4 to 68.1) |
Influenza virus titer is the quantity of influenza virus in a given volume within the samples obtained from nasal swabs. If influenza virus titer was less than the lower limit of quantification, the virus titer was imputed as 0.749 (log10TCID50/mL). A lower value indicates lower viral titer.
| log10 TCID50/ml | Baloxavir Marboxil | Placebo |
|---|---|---|
| Day 2 | -2.36 | -1.00 |
| Day 3 | -2.70 | -1.93 |
| Day 4 | -2.88 | -2.50 |
| Day 5 | -3.01 | -2.81 |
| Day 7 | -3.00 | -2.95 |
| Day 10 | -3.02 | -3.06 |
Influenza virus titer is the quantity of influenza virus in a given volume within the samples obtained from nasal swabs. If influenza virus titer was less than the lower limit of quantification, the virus titer was imputed as 0.749 (log10 TCID50/mL). A lower value indicates lower viral titer.
| percentage of participants | Baloxavir Marboxil | Placebo |
|---|---|---|
| Day 2 | 37.7 | 80.3 |
| Day 3 | 18.6 | 53.4 |
| Day 4 | 7.9 | 26.7 |
| Day 5 | 1.3 | 20.8 |
| Day 7 | 2.7 | 5.8 |
| Day 10 | 1.4 | 1.4 |
| log10 TCID50/mL*hours | Baloxavir Marboxil | Placebo |
|---|---|---|
| Area Under the Curve in Virus Titer | 291.68 ± 176.68 | 332.04 ± 183.63 |
Time to cessation of viral shedding by RT-PCR, in hours, is defined as the time between the initiation of study treatment and first time when the virus RNA by RT-PCR is below the limit of detection (2.05 for flu A and 2.83 for flu B log10 virus particles/mL)
| hours | Baloxavir Marboxil | Placebo |
|---|---|---|
| Time to Cessation of Viral Shedding by RT-PCR | 216.3 (211.3 to 239.8) | 261.1 (236.4 to NA) |
If the amount of virus RNA was less than the lower limit of quantification, the amount of virus RNA was imputed as 2.18 for flu A and 2.93 for flu B (log10 virus particles/mL)
| log10 virus particles/mL | Baloxavir Marboxil | Placebo |
|---|---|---|
| Day 2 | -0.98 | -0.66 |
| Day 3 | -1.54 | -1.19 |
| Day 4 | -2.35 | -1.84 |
| Day 5 | -2.91 | -2.39 |
| Day 7 | -3.15 | -2.96 |
| Day 10 | -3.69 | -3.21 |
If the amount of virus RNA was less than the lower limit of quantification, the amount of virus RNA was imputed as 2.18 for flu A and 2.93 for flu B (log10 virus particles/mL)
| percentage of participants | Baloxavir Marboxil | Placebo |
|---|---|---|
| Day 2 | 95.6 | 96.3 |
| Day 3 | 90.0 | 93.3 |
| Day 4 | 88.1 | 87.9 |
| Day 5 | 79.9 | 85.4 |
| Day 7 | 69.6 | 68.0 |
| Day 10 | 46.7 | 50.5 |
| log10 virus particles/mL*hours | Baloxavir Marboxil | Placebo |
|---|---|---|
| Area Under the Curve in the Amount of Virus RNA (RT-PCR) | 676.40 ± 371.72 | 740.15 ± 484.07 |
An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. A serious adverse event (SAE) is any significant hazard, contraindication, side effect that is fatal or life-threatening, requires hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability/ incapacity, is a congenital anomaly/ birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above.
| percentage of participants | Baloxavir Marboxil | Placebo |
|---|---|---|
| AEs | 45.2 | 50.0 |
| SAEs | 12.1 | 15.3 |
Discontinuation from study treatment.
| percentage of participants | Baloxavir Marboxil | Placebo |
|---|---|---|
| AEs | 1.3 | 3.2 |
| SAEs | 0.8 | 1.6 |
ALT = alanine aminotransferase AST = aspartate transaminase
| percentage of participants | Baloxavir Marboxil | Placebo |
|---|---|---|
| AST(U/L) or ALT (U/L) >3 x ULN | 4.6 | 8.9 |
| AST(U/L) or ALT (U/L) >5 x ULN | 0.8 | 3.2 |
| AST(U/L) or ALT (U/L) >10 x ULN | 0 | 1.6 |
| ng/mL | Baloxavir Marboxil |
|---|---|
| Day 1 - 30 minutes postdose | 37.82 ± 23.61 |
| Day 1 - 2 hours postdose | 75.06 ± 52.16 |
| Day 1 - 4 hours postdose | 95.85 ± 58.36 |
| Day 1 - 10 hours postdose | 64.47 ± 39.47 |
| Day 2 - 24 hours postdose | 53.36 ± 37.42 |
| Day 4 - Predose | 24.26 ± 15.87 |
| Day 4 - 30 minutes postdose | 49.16 ± 52.07 |
| Day 4 - 2 hours postdose | 109.66 ± 95.22 |
| Day 4 - 4 hours postdose | 117.69 ± 60.54 |
| Day 4 - 10 hours postdose | 94.08 ± 49.71 |
| Day 5 - 24 hours postdose | 77.98 ± 42.89 |
| Day 7 - predose | 23.31 ± 25.87 |
| Day 8 - 24 hours postdose | 105.00 ± NA |
| Visit 8 | 28.37 ± 61.61 |
| Hours(h)*nanogram(ng)/milliliter (mL) | Baloxavir Marboxil |
|---|---|
| Day 1 | 2820 ± 70.5 |
| Day 4 | 3170 ± 53.5 |
| ng/mL | Baloxavir Marboxil |
|---|---|
| Day 1 | 86.3 ± 64.6 |
| Day 4 | 123 ± 51.7 |
| Hours (h) | Baloxavir Marboxil |
|---|---|
| Day 1 | 18.9 ± NA |
| Day 4 | 23.4 ± 12.8 |
| ng/mL | Baloxavir Marboxil |
|---|---|
| Day 1 | 43.9 ± 74.4 |
| Day 4 | 67.1 ± 66.8 |
| Day 7 | 105 ± NA |
Collected over Randomization up to Day 35. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Baloxavir Marboxil | 4/239 (1.7%) | 29/239 (12.1%) | 44/239 (18.4%) |
| Placebo | 7/124 (5.6%) | 19/124 (15.3%) | 27/124 (21.8%) |
| Event | Baloxavir Marboxil | Placebo |
|---|---|---|
| PneumoniaInfections and infestations | 7/239 | 5/124 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 0/239 | 2/124 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 3/239 | 0/124 |
| Multiple organ dysfunction syndromeGeneral disorders | 2/239 | 0/124 |
| Pneumonia bacterialInfections and infestations | 2/239 | 1/124 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 2/239 | 1/124 |
| Cardiac failureCardiac disorders | 1/239 | 1/124 |
| Congestive cardiomyopathyCardiac disorders | 0/239 | 1/124 |
| ConstipationGastrointestinal disorders | 0/239 | 1/124 |
| Rectal haemorrhageGastrointestinal disorders | 0/239 | 1/124 |
| Event | Baloxavir Marboxil | Placebo |
|---|---|---|
| ConstipationGastrointestinal disorders | 10/239 | 6/124 |
| DiarrhoeaGastrointestinal disorders | 8/239 | 6/124 |
| Hepatic enzyme increasedInvestigations | 6/239 | 5/124 |
| HypokalaemiaMetabolism and nutrition disorders | 9/239 | 5/124 |
| HeadacheNervous system disorders | 9/239 | 2/124 |
| NauseaGastrointestinal disorders | 7/239 | 4/124 |
| PneumoniaInfections and infestations | 5/239 | 4/124 |
| Age, Continuous(Years) | Baloxavir Marboxil | Placebo | Total |
|---|---|---|---|
| Mean | 58.0 ± 19.8 | 61.6 ± 20.3 | 59.2 ± 20.0 |
| Sex: Female, Male(Participants) | Baloxavir Marboxil | Placebo | Total |
|---|---|---|---|
| Female | 117 | 56 | 173 |
| Male | 122 | 68 | 190 |
| Race/Ethnicity, Customized(Participants) | Baloxavir Marboxil | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 30 | 16 | 46 |
| Not Hispanic or Latino | 203 | 106 | 309 |
| Not Stated | 4 | 1 | 5 |
| Unknown | 2 | 1 | 3 |
| Race/Ethnicity, Customized(Participants) | Baloxavir Marboxil | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 4 | 0 | 4 |
| Asian | 39 | 22 | 61 |
| Black or African American | 7 | 2 | 9 |
| Native Hawaiian or other Pacific Islander | 1 | 0 | 1 |
| White | 181 | 95 | 276 |
| Unknown | 7 | 5 | 12 |
Showing the first 100 of 170 sites across 28 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Ran from Jan 2019 to primary completion in Mar 2020, 14 months.
Results were first posted in Nov 2020, 8 months after primary completion.
Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 14 months is above that.
Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baloxavir